Through next-generation sequencing, tumor samples were subjected to mutational profiling, and an in-frame gene rearrangement involving IRF2BP2 exon 1 and NTRK1 exons 8–16 was identified. This evidence concerns the gene IRF2BP2 and neoplasm.